الرئيسية › سرطان البروستاتا › إلينوي › Chicago
التجارب السريرية لـ سرطان البروستاتا في Chicago، IL
45 دراسات لـ سرطان البروستاتا تبحث عن مشاركين في مواقع داخل وحول Chicago (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
جارٍ التسجيلالمرحلة 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 2
- University of Illinois Cancer Center, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
جارٍ التسجيلالمرحلة 3
- University of Illinois Chicago, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
جارٍ التسجيلالمرحلة 2/3
- University of Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
جارٍ التسجيلالمرحلة 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
جارٍ التسجيلالمرحلة 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
جارٍ التسجيلالمرحلة 1
- University of Illinois Hospital & Health Sciences System, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Chicago Hospital, Chicago
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
جارٍ التسجيلالمرحلة 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- و 1 أخرى
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
جارٍ التسجيل
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
جارٍ التسجيلالمرحلة 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
جارٍ التسجيلالمرحلة 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
جارٍ التسجيلالمرحلة 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
جارٍ التسجيلالمرحلة 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
جارٍ التسجيلالمرحلة 3مرحباً بالمتطوعين الأصحاء
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
جارٍ التسجيلالمرحلة 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
جارٍ التسجيلالمرحلة 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
جارٍ التسجيلالمرحلة الأولى المبكرةمرحباً بالمتطوعين الأصحاء
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
جارٍ التسجيلالمرحلة 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
جارٍ التسجيلدراسة رصدية
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
جارٍ التسجيلالمرحلة 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
جارٍ التسجيلالمرحلة 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
جارٍ التسجيل
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
جارٍ التسجيلالمرحلة 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
جارٍ التسجيل
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
جارٍ التسجيلالمرحلة 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
جارٍ التسجيل
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
جارٍ التسجيلالمرحلة 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
جارٍ التسجيلدراسة رصدية
- The University of Chicago, Hyde Park · على بُعد 5 ميل
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
جارٍ التسجيلالمرحلة 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
جارٍ التسجيلالمرحلة 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
جارٍ التسجيلدراسة رصدية
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
جارٍ التسجيل
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
جارٍ التسجيلالمرحلة 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
جارٍ التسجيلدراسة رصدية
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
جارٍ التسجيلالمرحلة 4
- University of Chicago Medical Center, Chicago
تجارب سرطان البروستاتا في مدن أخرى
- New York City, NY103 دراسات
- Houston, TX76 دراسات
- Los Angeles, CA61 دراسات
- Boston, MA60 دراسات
- St. Louis, MO47 دراسات
- San Francisco, CA45 دراسات
- Seattle, WA44 دراسات
- Philadelphia, PA44 دراسات
- Nashville, TN43 دراسات
- Baltimore, MD42 دراسات
- Washington, DC38 دراسات
- Dallas, TX36 دراسات
دراسات أخرى في Chicago
- سرطان الرئة غير صغير الخلايا61 دراسات
- سرطان الثدي58 دراسات
- السرطان (جميع الأنواع)52 دراسات
- السرطان النقيلي45 دراسات
- السمنة42 دراسات
- سرطان الرئة41 دراسات
- سرطان المبيض36 دراسات
- السكتة الدماغية34 دراسات
- قصور القلب32 دراسات
- سرطان القولون والمستقيم32 دراسات
- زيادة الوزن28 دراسات
- ابيضاض الدم النقوي الحاد27 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 01/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.